

RECEIVED

JUL 16 2002
Patent
Docket No: 5491305108

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900

In re Application of:

CROOKS, et al

Serial No.: 10/027,272

Filed: December 21, 2001

For: SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES

Group Art Unit:

Examiner:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on:

Date

July 11, 2002

Signature

Amber M. Stancic

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97-1.98, copies of the documents listed on the attached form PTO-1449 are enclosed for consideration by the Examiner during examination of the above-identified patent application.

Should a First Office Action on the merits be mailed prior to the filing of this Disclosure Statement, please charge the requisite \$180.00 fee (pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p)) to Deposit Account No. 13-3723.

Respectfully submitted,

Registration Number 38,729	Telephone Number (651) 575-4914
Date 11 July 02	

By

M. Howard
MarySusan Howard

Office of Intellectual Property Counsel
3M Innovative Properties Company
P.O. Box 33427
St. Paul, Minnesota 55133-3427
Facsimile: (651) 736-3833

07/19/2002 AOSMANI 00000062 133723 10027272

01 FC:126

180.00 CH